Moderna, Inc.

Registration Deadline:

10/08/2024

Submit Your Information

A securities class action has been filed in the USDC — MA. against Moderna, Inc. (MRNA) (“Moderna” or the “Company”), on behalf of all persons or entities that purchased or otherwise acquired Moderna securities between January 18, 2023 and June 25, 2024, both dates inclusive (the “Class Period”).

 

Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA (“mRNA”) therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the U.S., Europe, and internationally. The Company’s products include, inter alia, mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (“RSV”) vaccine, intended to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.

 

 

The claim arises on June 26, 2024, when in a presentation before the Centers for Disease Control and Prevention’s (“CDC”) Advisory Committee on Immunization Practices, Moderna disclosed that after 18 months, mRNA-1345 proved only 49.9% to 50.3% effective against multiple symptoms of lower respiratory tract disease-a significantly lower efficacy rate than vaccines produced by Moderna’s competitors.

 

Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:

 

(1) mRNA-1345 was less effective than Defendants had led investors to believe;

(2) accordingly, mRNA-1345’s clinical and/or commercial prospects were overstated; and

(3) as a result, the Company’s public statements were materially false and misleading at all relevant times, thereby harming investors.

 

 

 

If you purchased Moderna securities during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

 

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.